Free Trial
→ Feds Just Admitted It—They Can Take Your Cash (From Priority Gold) (Ad)
NASDAQ:ALZN

Alzamend Neuro 7/27/2023 Earnings Report

Alzamend Neuro logo
$0.76 -0.03 (-3.68%)
Closing price 04/15/2025 04:00 PM Eastern
Extended Trading
$0.78 +0.02 (+1.97%)
As of 06:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings HistoryForecast

Alzamend Neuro EPS Results

Actual EPS
-$4.50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Alzamend Neuro Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alzamend Neuro Announcement Details

Quarter
Date
7/27/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Remove Ads

Alzamend Neuro Earnings Headlines

Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?
March 28, 2025 | insidermonkey.com
Alzamend Neuro CFO David Katzoff acquires $5,048 in common stock
March 26, 2025 | investing.com
Feds Just Admitted It—They Can Take Your Cash
Here’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousands of smart, forward-thinking individuals are making the move—out of the system and into real, untouchable assets. Because once your funds are frozen, it’s too late.
April 16, 2025 | Priority Gold (Ad)
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital
March 25, 2025 | globenewswire.com
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
March 18, 2025 | globenewswire.com
Alzamend Neuro files to sell 75.775M shares of common stock for holders
March 14, 2025 | markets.businessinsider.com
See More Alzamend Neuro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alzamend Neuro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alzamend Neuro and other key companies, straight to your email.

About Alzamend Neuro

Alzamend Neuro (NASDAQ:ALZN), an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

View Alzamend Neuro Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles